Thema: US30233G2093
EYPT, US30233G2093
iphone-5183942_1920.jpg - Foto: THN
EyePoint Pharmaceuticals stock pivots to DME after wet AMD setback
EyePoint Pharmaceuticals stock faces a new DME focus after wet AMD trials missed their primary endpoint. Two Phase III studies are fully enrolled.
ad-hoc-news.de, 10.11.26 22:54 Uhr
EYPT, US30233G2093
EyePoint Pharmaceuticals stock at 0.31 euros in evening ...
EyePoint Pharmaceuticals stock remains tied to a Phase 3 retinal-drug program. Investors are watching clinical progress as the company advances its pipeline.
ad-hoc-news.de, 30.10.26 19:37 Uhr
EYPT, US30233G2093
Mizuho sets USD 0.50 target for EyePoint Pharmaceuticals ...
EyePoint reported USD 0.51 million in second-quarter 2026 revenue. EyePoint stock last traded at USD 0.36 on October 27, 2026 at 4:00 p.m. ET.
ad-hoc-news.de, 27.10.26 22:37 Uhr
EYPT, US30233G2093
JonesTrading downgrades EyePoint Pharmaceuticals stock to ...
Q2 brought a USD 94.5 million GAAP loss in the quarter ended June 30, 2026. EyePoint Pharmaceuticals stock faces a USD 1.00 target, down from USD 5.00.
ad-hoc-news.de, 24.10.26 20:59 Uhr
EYPT, US30233G2093
EyePoint Pharmaceuticals stock closed at EUR 2.76 up 3.76 ...
JonesTrading set USD 20.00 on September 29, 2026. EyePoint Pharmaceuticals stock closed EUR 2.76 in Frankfurt on October 16, 2026, up 3.76 percent.
ad-hoc-news.de, 17.10.26 21:08 Uhr
EYPT, US30233G2093
EyePoint Pharmaceuticals stock fell 3.08 percent as LUCIA ...
EyePoint Pharmaceuticals stock was last at USD 3.15 on October 5, while 11 analysts set a USD 25.70 average target. Q2 revenue reached USD 507,000.
ad-hoc-news.de, 06.10.26 09:56 Uhr
Eyepoint, Pharmaceuticals
Eyepoint Pharmaceuticals: A Critical Two-Year Timeline for ...
